17 Apr 2018

Next Frontier Biosciences Expands Verra Wellness Product Lines into California via Partnership with BAS Research

DENVER, April 12, 2018 /PRNewswire/ — Next Frontier Biosciences, a Colorado-based cannabis drug development and commercialization firm, today announced a partnership with BAS Research to bring its Verra Wellness line of premium cannabis-infused products to the California medical and adult-use marijuana markets. The Verra Wellness line of sublingual sprays and topical salves are anticipated to be available in California by Q3 2018.

 

“Expanding into California allows Next Frontier Biosciences to tap into the state’s multibillion-dollar marijuana industry–gaining access to what is projected to be the world’s largest legal cannabis market,” said Marc Graboyes, Co-Founder and CEO of Next Frontier Biosciences. “Our cutting-edge Verra Wellness products are designed to meet the California market’s need for clean, consistent and trustworthy products that allow consumers the ability to manage their dose. Our partner, BAS Research, shares this vision for the industry’s future and we are excited to work together to pursue our mutual goal of providing consumers with best-in-class cannabis products that are safe, effective and discreet.”

 

Read more PRN Newswire site.

13 Feb 2018

Press Release: Next Frontier Biosciences Assembles Distinguished Research and Development Team

Press Release: Next Frontier Biosciences Assembles  Distinguished Research and Development Team

 

Next Frontier Biosciences Assembles

Distinguished Research and Development Team

 

Biotech company draws upon highly experienced scientists and researchers

to develop and commercialize best-in-class cannabis products

 

DENVER (February 13, 2018) – Colorado-based biotech company Next Frontier Biosciences today announced the assembly of its Research and Development Team, enhancing the company’s lineup of accomplished biotechnology executives and research scientists. After successfully launching its first generation Verra Wellness line of products in the Colorado adult-use and medical marijuana markets in November, the company is seeking to expand into emerging cannabis markets, both domestically and internationally, and plans to introduce at least two new products in 2018.

 

“Our Research and Development Team plays an integral role in creating new products and supporting our expansion strategy, including developing robust manufacturing processes, product specifications, and standard operating procedures” said Marc Graboyes, Co-Founder and CEO of Next Frontier Biosciences. “In turn, their work allows us to pursue valuable intellectual property rights and implement a broad-based licensing program wherein our proprietary formulations and brands are made available to third parties who possess the licenses and facilities required to manufacture, sell and distribute our best-in-class cannabis products in their respective markets.”

 

Leading the team is Paul Johnson, Ph.D., Co-Founder and Chief Scientific Officer of Next Frontier Biosciences. “This group of bright, accomplished scientists and researchers is a major asset to Next Frontier and its Verra Wellness brand, fueling the continued growth of our product pipeline and propelling us into new emerging markets,” Dr. Johnson said.

 

 

Dr. Johnson has over four decades of experience in the pharmaceutical industry. He is an expert in intranasal drug development and delivery systems, and has authored or invented over 100 patents and scientific publications. Dr. Johnson has substantial experience in drug delivery and development, molecular diagnostics, cell biology, molecular biology and biochemistry/biophysics. In addition, he has led research and development activities for FDA approved drugs including Betaseron, the first-ever FDA approved drug to treat multiple sclerosis. He received a B.S. in Molecular Biology from the State University of New York, a Ph.D. in Biochemistry from the Roswell Park Cancer Institute, and conducted his postdoctoral training in biophysics and biology under an American Cancer Society fellowship at the California Institute of Technology.

 

 

Dorothy “Dot” Colagiovanni, Ph.D. serves as Vice President of Product Development at Next Frontier Biosciences, where she is responsible for the day-to-day management of Next Frontier’s research and development activities as well as supporting the commercialization of the company’s products. She has over two decades of pharmaceutical development experience with an emphasis on project management, pharmacology and toxicology. Prior to joining the company, Dr. Colagiovanni held scientific leadership roles with Nivalis Therapeutics and Replidyne. She also held research positions with OSI Pharma, Gilead Sciences and Amgen. Dr. Colagiovanni has a broad range of development experience, starting from early drug discovery and clinical trials through regulatory approval and commercial launch. She completed her Ph.D. at University of Colorado Health Sciences Center in Molecular Toxicology and a postdoctoral fellowship at Amgen Boulder.

 

“Our ultimate objective is to make the benefits of cannabis more widely available through discreet, smoke-free delivery technologies. The desire to bring healthier and safer alternatives to the market is the common thread uniting our team and motivating our efforts in the lab every day,” Dr. Colagiovanni said. “Each member brings a unique area of expertise to the table, which lends itself to continued innovation–supporting our overarching goal at Next Frontier Biosciences.”

 

Stephen Cape, Ph.D., is Next Frontier’s Director of Formulation Sciences. Dr. Cape has more than 15 years of experience developing formulations of pharmaceuticals, biologicals and vaccines for alternative routes of delivery, including sublingual, nasal, transdermal and inhalation. Prior to joining Next Frontier, he held technical and project leadership roles at the University of Colorado and Aktiv-Dry LLC (Boulder, CO). Dr. Cape led the formulation and spray-drying process development of the first inhaled dry powder measles vaccine to successfully complete a Phase I clinical trial. He has broad experience in early-stage basic R&D, formulation and process development, and technology transfer for GMP manufacturing.

 

“It’s an exciting time to work in the emerging cannabis space, and our team is advancing Next Frontier Biosciences to the forefront of the cutting-edge research and development that will elevate the industry to a higher standard of scientific excellence,” Dr. Cape said. “The work we contribute in the lab will yield a positive, tangible impact as consumers find more consistent and reliable options with the comfort and flexibility to select their preferred method of administration.”

 

Kris Chupka, Next Frontier’s Director of Analytical Chemistry brings to the team over 18 years of research and development analytical experience from the electronics and pharmaceutical industries. His specialties are chromatographic separations, mass spectrometry and thermal mechanical analysis. Prior to joining Next Frontier Biosciences, Mr. Chupka held analytical chemistry leadership roles for Atotech, Novartis, Mylan and Western Digital. He has a proven track record in supportive analytical development from conceptual research and development to commercial product support.

 

“Our analytical capabilities–including a high resolution mass spectrometer–provide us with the ability to fully characterize all aspects of Next Frontier Biosciences products, from flower to filled device,” Mr. Chupka said. “Consumers can rest assured knowing that the Next Frontier Biosciences name represents a profound commitment to sophisticated, well-characterized products that are unmatched in quality.”

 

 

Susan Schwarz serves as Senior Analytical Chemist at Next Frontier Biosciences. Ms. Schwarz is a biotechnology professional with extensive experience in all stages of biopharmaceutical development from drug discovery to cGMP manufacturing. She has utilized numerous types of analytical instrumentation throughout her career. Ms. Schwarz has held positions from Quality Control Chemist (Somatogen) working with recombinant hemoglobin to Analytical Chemist (Takeda Vaccines) for process scale up (from 1L to 50L) and tech transfer of a norovirus vaccine using single-use technology to a contract manufacturing organization.

 

“The scalable process that results from our Research and Development team will serve to support our technology transfer and licensing program, ensuring that the Verra Wellness suite of purified cannabinoid-infused products can reach new demographics in new regions,” Ms. Schwarz said.

 

 

The newest member of the research team, Andres Gandara, joins as Formulation Scientist. A graduate of the University of Colorado with a bachelor’s degree in Chemical Engineering, Mr. Gandara comes to Next Frontier Biosciences with a strong engineering and business background, having previously worked at Bayer CropScience in Guatemala, Transform Energy in Golden, and most recently at Custom Solar in Boulder.

 

“Next Frontier Biosciences is a proven leader in product innovation. Participating in the rigorous formulation process from beginning to end–all while playing an active role in bringing novel and effective cannabinoid-infused products to new markets–is extremely rewarding,” Mr. Gandara said.

 

Founded in 2014, Next Frontier Biosciences has assembled a team of highly experienced biotech executives and research scientists with over 120 years of pharmaceutical drug development experience. The company employs a traditional scientific approach to product development that includes advanced purification, analytical and chemical formulation methods. Next Frontier Biosciences’ proprietary formulations were carefully developed and optimized for improved delivery via nasal, sublingual and topical administration with a focus on providing unparalleled quality, consistency and reproducibility.

 

For more information or to schedule an interview with Next Frontier Biosciences, please contact Shawna McGregor at 917-971-7852 or shawna@rosengrouppr.com.

 

About Next Frontier Biosciences: At Next Frontier Biosciences, we believe that cannabinoid purification and scientific formulation are the keys to unlocking the power of the plant and developing safer and more effective cannabinoid-based products. Scientifically formulated to provide accurate dosing, improved bioavailability and optimized cannabinoid profiles, our Verra Wellness line of products, including nasal mists, sublingual sprays and topical salves, offer fast acting and consistent results. Additionally, their unique modes of administration are discreet and effective, providing both medical and adult-use cannabis consumers with desirable alternatives to smoking, vaporizing or eating cannabis-infused products. At Next Frontier Biosciences, we maintain an unyielding commitment to scientific excellence and integrity, so our products aren’t just created from cannabis—they’re derived from truth.

 

For more information, visit http://nextfrontierbio.com/. Follow us on Facebook, Twitter, Instagram and LinkedIn.

 

 

# # #

06 Dec 2017

Cannabis Business Executive: Next Frontier Biosciences Launches Revolutionary Product Line Verra Wellness

Cannabis Business Executive: Next Frontier Biosciences Launches Revolutionary Product Line Verra Wellness

Next Frontier Biosciences announced today the launch of its Verra Wellness line of purified cannabinoid products into the medical and adult-use marijuana markets in Colorado. The Verra Wellness products are scientifically formulated for improved delivery via nasal, sublingual and topical administration and provide patients and consumers with safe, effective and discreet alternatives to smoking, vaporizing or eating cannabis-infused products. The Verra Wellness offering includes the world’s first cannabis nasal mist. The line also consists of a sublingual spray and a topical salve.

 

Read more on Cannabis Business Executive.

To learn more about the revolutionary Verra Wellness product line, visit: https://verrawellness.com/

16 Oct 2017

Press Release: Next Frontier Biosciences Expands Ranks with New Regional Sales Manager

DENVER (October 11, 2017) – As Next Frontier Biosciences prepares to launch its Verra Wellness line of purified cannabinoid products in November, the Colorado-based biotech company has enhanced its experienced sales lineup with the addition of a new Regional Sales Manager, Colin Osborne.

 

In preparation for the product launch, Osborne plays a key role in generating a new customer base, forging and fostering strong relationships and educating clients on which products best suit their needs. In addition, he  develops and implements an optimal sales strategy and product promotion while ensuring brand integrity.

 

Prior to joining Next Frontier Biosciences, Osborne worked in sales for nine years, notably serving as Sales Manager at Weaver Fundraising, LLC. He also served as Enterprise Software Sales Executive at BigMachines, Inc. and Executive Sales Representative at CBLPath, Inc. He later discovered a passion for the cannabis industry as Account Representative and Project Manager at ALl Packaging Company in Aurora, Colorado, and most recently in his role as Retail Associate at The Green Solution in Denver. A former Marine Officer, Osborne earned his bachelor’s degree from Gettysburg College and his master’s degree from Villanova University.

 

“Colin brings a strong and unique combination of leadership, sales and cannabis industry experience to Next Frontier Biosciences, making him well equipped to lead our regional sales team in introducing Verra Wellness to the market,” said Beth Dresser, Senior Director of Sales and Marketing at Next Frontier Biosciences. “We welcome his insights and know that our clients and staff will benefit from his guidance as we launch the brand in Colorado and establish ourselves as a global cannabis-infused products leader in other markets.”

 

For more information or to schedule an interview with Next Frontier Biosciences, please contact Shawna McGregor at 917-971-7852 or shawna@rosengrouppr.com.

 

About Next Frontier Biosciences: Next Frontier Biosciences is a Colorado-based biotech company focused on developing and commercializing best-in-class purified cannabinoid products that are scientifically formulated for improved delivery. Comprised of an experienced group of biotechnology executives and research scientists, Next Frontier Biosciences is pioneering the development of purified cannabinoid products that provide accurate dosing, improved bioavailability and optimized cannabinoid profiles for fast acting and consistent results. Next Frontier Biosciences’ goal is to leverage its proprietary formulations and premium brand strategy to become a global leader in the market for next-generation cannabis infused products.

 

The company is led by a talented group of biotech executives and research scientists that help set it apart from the competition. Marc Graboyes, J.D., Next Frontier Biosciences’ co-founder and Chief Executive Officer, is responsible for leading the development and execution of the company’s long-term strategy as well as the day-to-day management of the company’s affairs. Mr. Graboyes has over two decades of experience working with emerging growth companies and the investors that support them, including eight years as Senior Vice President and General Counsel of Allos Therapeutics, Inc., a biotech company that he helped take public and sell for nearly $200 million. Prior to that, he was a corporate attorney with several large national law firms, including nearly five years with Cooley LLP. Mr. Graboyes is a seasoned business executive and attorney with deep experience in the areas of strategic planning, corporate finance, corporate development, technology transactions, and mergers and acquisitions, among other areas.

 

Dr. Paul Johnson, Ph.D., Next Frontier Biosciences’ co-founder and Chief Scientific Officer, has over four decades of experience in the pharmaceutical industry. He is an expert in intranasal drug development and delivery systems, and authored or invented over 100 patents and scientific publications. Dr. Johnson has experience in drug delivery and development, molecular diagnostics, cell biology, molecular biology and biochemistry/biophysics. In addition, he has led research and development activities for FDA approved drugs including Betaseron, the first-ever FDA approved drug to treat multiple sclerosis. He received a B.S. in Molecular Biology from the State University of New York, a Ph.D. in Biochemistry from the Roswell Park Cancer Institute, and conducted his postdoctoral training in biophysics and biology under an American Cancer Society fellowship at the California Institute of Technology.

 

Dr. Dorothy “Dot” Colagiovanni, Ph.D., Next Frontier Biosciences’ Vice President of Pharmaceutical Development, is responsible for the day-to-day management of the company’s research and development activities as well as supporting the commercialization of the company’s products. She has over two decades of pharmaceutical development experience with an emphasis on project management, pharmacology and toxicology. Prior to joining the company, Dr. Colagiovanni held scientific leadership roles with Nivalis Therapeutics and Replidyne, and she also held research positions with OSI Pharma, Gilead Sciences and Nexstar. Dr. Colagiovanni has a broad range of pharmaceutical development experience, starting with early drug discovery and clinical trials through regulatory approval and commercial launch. She completed her Ph.D. at University of Colorado Health Sciences Center in Molecular Toxicology and a postdoctoral fellowship at Amgen in hematotoxicology.

 

For more information, visit http://nextfrontierbio.com/. Follow us on Facebook, Twitter, Instagram and LinkedIn.

 

# # #

 

11 Oct 2017

Press Release: Next Frontier Biosciences Introduces Scientific Advisory Board

DENVER (October 4, 2017) – Colorado-based biotech company Next Frontier Biosciences today announced its Scientific Advisory Board, rounding out the company’s expert lineup of biotech and cannabis professionals. With plans to launch its Verra Wellness line of purified cannabinoid products for the medical and adult-use marijuana markets in Colorado this month, Next Frontier Biosciences, a trailblazer in the cannabis space, continuously strives to use high quality and purified ingredients that provide safe and natural alternatives for cannabis patients and adult-use consumers alike.

 

“Research and scientific formulation are at the heart of everything we do,” said Paul Johnson, Ph.D., Co-Founder & Chief Scientific Officer of Next Frontier Biosciences. “Backed by a team of educated and highly experienced thought leaders, Next Frontier Biosciences is emerging at the forefront of innovation in the cannabis industry. Ahead of our upcoming product launch, we are proud to have engaged an accomplished group of professionals that will uphold and advocate for our company values, demonstrating strong commitment to cutting-edge research, scientific excellence and integrity.”

 

Dr. Rav Ivker, D.O., joins the Scientific Advisory Board as a holistic family physician, cannabis clinician, health educator, spiritual counselor, author and healthcare visionary. In his current practice, Fully Alive Medicine in Boulder, Colorado, Dr. Ivker’s primary focus is the treatment and prevention of chronic pain using a holistic approach that includes medical marijuana.

 

Dr. Ivker has been practicing medicine for more than 45 years. His original practice, Columbine Medical Center, became the first combined family practice/minor emergency center in Colorado, a forerunner of today’s Urgent Care Centers. He is the Co-Founder and Past-President of the American Board of Integrative Holistic Medicine, a Past-President of the American Holistic Medical Association and the author of the best-selling book, Sinus Survival.

 

His latest book, Cannabis for Chronic Pain: A Proven Prescription for Using Marijuana to Relieve Your Pain & Heal Your Life, provides the first authoritative and comprehensive guide for treating chronic pain with medical marijuana. Published by Simon & Schuster in September, this excellent resource can be found in bookstores and online.

 

“On the market today, there is currently an unmet medical need for well-characterized, purified cannabinoid products that are scientifically formulated to provide accurate dosing, improved bioavailability and reduced psychogenic effects,” Dr. Ivker said. “However, Next Frontier Biosciences is developing those very products, ultimately closing the gap and revolutionizing the industry by providing the public with a safe, non-inhalable and highly effective option that allows them to function well while relieving a myriad of uncomfortable symptoms.”

 

Shawn Zinnen, Ph.D., is Chief Executive Officer of MBC Pharma Inc., a pharmaceutical company focused on discovering and developing novel medicines for the treatment of oncology, bone and infectious diseases. Dr. Zinnen joins the Scientific Advisory Board as an experienced pharmaceutical executive and discovery scientist with a demonstrated track record of success in preclinical and early-stage clinical drug development. Dr. Zinnen has managed interdisciplinary teams of both industry and academic scientists solving pharmacology-related problems for diseases ranging from cancer to asthma to macular degeneration.

 

Prior to joining MBC Pharma, Dr. Zinnen served in various roles of increasing responsibility at Sirna Therapeutics, Inc. (previously Ribozyme Pharmaceuticals Inc.), where he helped advance drug compounds from discovery stage and into human clinical trials. Dr. Zinnen graduated with a Ph.D. in Biochemistry and Genetics from Duke University and conducted post-doctoral research at the University of Colorado at Boulder as an NIH Fellow. He has authored or coauthored 17 papers and 54 patents.

 

“I am impressed with Next Frontier Biosciences’ experienced team and their use of solid analytical science to advance the industry,” Dr. Zinnen said. “I look forward to bringing my own background in pharmaceutical development to help further investigate the healing potential of cannabis on a broader scale.”

 

Completing the board is Laurie K. Mischley, ND Ph.D. MPH. Dr. Mischley joins the team with a degree in naturopathic medicine (ND) from Bastyr University, as well as degrees in epidemiology (MPH) and nutritional sciences (Ph.D.) from the University of Washington.

 

Dr. Mischley is Principle Investigator of the Survey of Cannabis Use (www.CannabisSurvey.org), an international study that gives cannabis users a forum to tell physicians, researchers, policy-makers and the public why and how they use cannabis. She has published on the medical use of cannabis, including the recent Journal of Pain Research article “Cannabis as a Substitute for Prescription Drugs – a Cross-Sectional Study,” and differing experiences between men and women who use cannabis. In addition, she has recently completed a study on cannabis use for Parkinson’s disease tremor.

 

Most of Dr. Mischley’s work is focused on identifying the nutritional requirements unique to individuals with neurodegenerative diseases. She founded the Social Purpose Corporation, NeurRx, developed an outcome measure to assess PD severity, www.PROPD.org, and is author of the books Natural Therapies for Parkinson’s Disease and Survey of Cannabis Use: Confessions, Insights, and Opinions.

 

“Patients and consumers need to know that they have options,” Dr. Mischley said. “Furthermore, they need to be educated on what those options are so that they can feel empowered to make the right decision when it comes to finding a well-suited cannabis product. I am passionate about helping to inform the public about Next Frontier Biosciences’ line of products as a research-based, science-backed option with the capability of changing their lives for the better.”

 

Founded in 2014, Next Frontier Biosciences has assembled a team of highly experienced biotech executives and research scientists with over 120 years of pharmaceutical drug development experience. The company employs a traditional scientific approach to product development that includes advanced purification, analytical and chemical formulation methods. Next Frontier Biosciences’ proprietary formulations were carefully developed and optimized for improved delivery via nasal, sublingual and topical administration with a focus on providing unparalleled quality, consistency and reproducibility.

 

For more information or to schedule an interview with Next Frontier Biosciences, please contact Shawna McGregor at 917-971-7852 or shawna@rosengrouppr.com.

07 Sep 2017

Press Release: Cannabis For Chronic Pain By Dr. Rav Ivker

Cannabis For Chronic Pain 

By: Dr. Rav Ivker

 

“An informative approach to an increasingly mainstream topic, and even skeptics may find Ivker’s positive energy, encouraging view of life, and generous sprinkling of inspirational quotes from the likes of F. Scott Fitzgerald and Albert Einstein beneficial.”

Booklist

 

Cannabis for Chronic Pain presents a long-awaited, rational discussion of the potential of cannabis as a therapeutic tool across a wide spectrum of challenging medical conditions. From the perspectives of both patient and clinician, Dr. Ivker provides compelling evidence to support judicious use of cannabis, especially for chronic pain, and reveals that in terms of risk versus benefit, cannabis outshines anything pharmaceutical.”

—David Perlmutter, MD, #1 New York Times bestselling author of Grain Brain and Brain Maker

 

“This book is a valuable resource for anyone suffering with chronic pain. By establishing the standard of care for the emerging field of cannabis medicine, it guides readers to quickly and safely relieve their pain, providing an effective alternative to opioids. But even more important it helps readers address the causes of their pain while providing a holistic self-care approach to long-term relief, utilizing state-of-the-art integrative and functional medicine.”

—Mark Hyman, MD, #1 New York Times bestselling author of Eat Fat, Get Thin

 

 

With medical marijuana legalized in more than half of the country’s 50 states, legal marijuana sales have created a multi-billion dollar industry. In CANNABIS FOR CHRONIC PAIN (September 12, 2017; Touchstone; $25; Hardcover; ISBN: 978-1-5011-5588-8)—the first authoritative and comprehensive guide for treating chronic pain with medical marijuana—holistic family physician DR. RAV IVKER provides essential information and instruction on how to use marijuana to treat a variety of physical and emotional pain conditions. Dr. Ivker also serves as a Scientific adviser to Next Frontier Biosciences, the formulators of Verra Wellness.

 

Dr. Ivker has been practicing family medicine for the past forty-five years. Since 1987, his practice has focused on treating and preventing chronic illness using a whole-person (body-mind-spirit) approach. After suffering an extremely painful case of shingles and experiencing firsthand the dramatic relief provided by medical marijuana, he was inspired to write this book and broadcast the message that cannabis is a safe and highly effective alternative to the addictive and often deadly opioids. In 2014, there were fifty-two deaths every day from opioid overdose.

 

This integration of cannabis into a holistic medical treatment program has proven to be remarkably successful for quickly relieving pain providing long-term relief, reducing and eliminating opioids, addressing the causes of disease, and for helping patients to heal their lives. In his Fully Alive Medicine practice he’s treated more than 7,000 chronic pain patients with medical marijuana.

 

Chronic pain affects more than 100 million Americans—more than heart disease, diabetes, and cancer combined. As the number of patients using medical marijuana increases yearly, misconceptions about cannabis and whether it’s harmful or dangerous still abound. In CANNABIS FOR CHRONIC PAIN, Dr. Ivker dispels many of the misconceptions and presents marijuana’s risks and therapeutic potential for healing anyone afflicted with chronic pain.

 

The book guides readers through the various safe means of cannabis treatment and addresses a range of topics such as:

  • The common requirements across states for patients to obtain medical marijuana licenses.
  • The pros and cons of the delivery methods, including smoking, vaporizing, transdermal patches, and even juicing.
  • Driving while under the influence of marijuana and common side effects of THC.
  • The differences between the two primary Sativa and Indica strains and their varying effects on common chronic pain conditions.
  • The most effective hybrid pain relievers to purchase.

 

Complete with success stories from real-life patients, CANNABIS FOR CHRONIC PAIN guides readers through the cannabis and holistic treatment program for specific chronic pain conditions—from arthritis, back pain, migraines, fibromyalgia, neuropathy, shingles, menstrual cramps, IBS, Crohn’s Disease, anxiety, insomnia, depression, and pain from cancer or its treatment. Dr. Rav offers step-by-step instructions on the benefits and appropriate use of medical marijuana and complementary healing therapies and practices. (For example, cannabis does not have to be smoked or ingested to be effective! Transdermal patches, tablets, sublingual and nasal sprays, and drops can achieve the same, if not better, pain relief.) It’s now possible to create a distinct cannabis prescription for varying types of chronic pain. The book also doubles as an instructional manual for industry workers—budtenders and cannabis clinicians—to advise patients on the appropriate use of medical marijuana.

 

CANNABIS FOR CHRONIC PAIN presents cannabis from a scientific, medical, and mystical perspective, making a compelling case for medical marijuana as a safe and effective alternative to opioids.

 

 

Dr. Rav Ivker is a holistic family doctor with nearly five decades of experience. He’s written seven holistic healing books, most notably Sinus Survival He received his DO degree from the Philadelphia College of Osteopathic Medicine and is a past-president and cofounder of the American Board of Integrative Holistic Medicine (ABIHM), a past-president of the American Holistic Medical Association (AHMA), and a Fellow of the American Academy of Family Physicians. He runs his own holistic medical practice, Fully Alive Medicine, in Boulder, Colorado.

 

 

Media Contact: Courtney Brach, 212.698.1296, Courtney.Brach@simonandschuster.com

07 Jun 2017

Next Frontier announces plans for product launch

Next Frontier Biosciences Brings Advanced Formulation Sciences to The World of Cannabis Product Development

DENVER (June 7, 2017) – Colorado-based biotech company Next Frontier Biosciences today announced plans to launch a suite of purified cannabinoid products for the medical and adult-use marijuana markets in Colorado in the fall of 2017. Next Frontier’s Verra Wellness line of products are scientifically formulated for accurate and consistent delivery of purified tetrahydrocannabinol (THC) and cannabidiol (CBD) in three different ratios via nasal mists and sublingual sprays. Verra Wellness will also offer a line of small batch topical salves designed to permeate skin and muscle tissue deeply without penetrating the blood stream or causing psychoactive effects.

 

“Next Frontier Biosciences’ Verra Wellness line of nasal, sublingual and topical products will provide cannabis patients and consumers with important alternatives to smoking, vaporizing or eating impure and poorly characterized cannabis products,” said Marc Graboyes, Next Frontier’s co-founder and Chief Executive Officer. “We plan to launch in Colorado in the third quarter of this year and will seek to expand into the 10 legal state markets by 2020. Our team of highly experienced research scientists will also continue enhancing and expanding our product offerings by incorporating new cannabinoids and developing additional product lines with a focus on improved absorption, or bioavailability.”

 

“Cannabinoids are the primary active ingredients in the cannabis plant and have demonstrated a wide range of therapeutic benefits for the treatment of chronic pain, anxiety, insomnia and post-traumatic stress disorder, among other conditions,” continued Dr. Paul Johnson, Ph.D., Next Frontier’s co-founder and Chief Scientific Officer. “At Next Frontier Biosciences, we believe that cannabinoid purification and scientific formulation are the keys to unlocking the power of the plant and developing safer and more effective cannabinoid-based products. We are reshaping the cannabis industry by designing a premium brand of trusted cannabis infused products that provide uniform composition, formulation and dosing in several discreet and highly consistent modes of administration.”

 

Founded in 2014, Next Frontier has assembled a team of highly experienced biotech executives and research scientists with over 120 years of pharmaceutical drug development experience. The company employs a traditional scientific approach to product development that includes advanced purification, analytical and chemical formulation methods. Next Frontier’s proprietary formulations were carefully developed and optimized for improved delivery via nasal, sublingual and topical administration with a focus on providing unparalleled quality, consistency and reproducibility.

 

“Next Frontier Biosciences is structured as an intellectual property and brand management company,” explained Mr. Graboyes. “We operate primarily through strategic collaborations with third parties who hold the licenses and approvals required to develop, manufacture and distribute our cannabis-infused products in their respective state markets. As such, we are actively seeking strategic partners to help bring our products to market in other states and countries throughout the world.”

 

Mr. Graboyes will speak at the National Cannabis Industry Association Cannabis Business Summit & Expo (June 12-14, 2017, Oakland Marriott City Center, Oakland, California) on the panel discussion “Unveiling The Future: A New Crop of Infused Products” on Tuesday, June 13 at 2:45pm. Mr. Graboyes will discuss NFB’s scientific approach to cannabis product development and future innovation.

 

For more information or to schedule an interview with Next Frontier Biosciences, please contact Shawna McGregor at 917-971-7852 or shawna@rosengrouppr.com.

 

About Next Frontier Biosciences:

 

Next Frontier Biosciences is a Colorado-based biotech company focused on developing and commercializing best-in-class purified cannabinoid products that are scientifically formulated for improved delivery. Comprised of an experienced group of biotechnology executives and research scientists, NFB is pioneering the development of purified cannabinoid products that provide accurate dosing, improved bioavailability and optimized cannabinoid profiles for fast acting and consistent results. NFB’s goal is to leverage its proprietary formulations and premium brand strategy to become a global leader in the market for next-generation cannabis infused products.

 

NFB is led by a talented group of biotech executives and research scientists that help set it apart from the competition. Marc Graboyes, J.D., NFB’s co-founder and Chief Executive Officer, is responsible for leading the development and execution of the company’s long-term strategy as well as the day-to-day management of the company’s affairs. Mr. Graboyes has over has over two decades of experience working with emerging growth companies and the investors that support them, including eight years as Senior Vice President and General Counsel of Allos Therapeutics, Inc., a biotech company that he helped take public and sell for nearly $200 million. Prior to that, he was a corporate attorney with several large national law firms, including nearly five years with Cooley LLP. Mr. Graboyes is a seasoned business executive and attorney with deep experience in the areas of strategic planning, corporate finance, corporate development, technology transactions, and mergers and acquisitions, among other areas.

 

Dr. Paul Johnson, Ph.D., NFB’s co-founder and Chief Scientific Officer, is responsible for leading the development and implementation of the company’s research and development programs, advising the company on scientific matters, evaluating data, and overseeing the company’s intellectual property strategy and patent portfolio. Dr. Johnson has over four decades of pharmaceutical industry experience and is a leading expert in the field of intranasal drug development and delivery systems. Prior to joining the company, he served as Chief Scientific Officer of PhaseRx Pharmaceuticals, Nastech Pharmaceuticals, and EpiGenX Pharmaceuticals. Prior to that, he held scientific leadership roles with Berlex Biosciences and SRI International. During his career, Dr. Johnson has authored over 100 patents and scientific publications, as well as two books on pharmaceutical discovery and development.

 

Dr. Dorothy “Dot” Colagiovanni, Ph.D., NFB’s Senior Director, Pharmaceutical Development, is responsible for the day-to-day management of the company’s research and development activities as well as supporting the commercialization of the company’s products. She has over two decade of pharmaceutical development experience with an emphasis on project management, pharmacology and toxicology. Prior to joining the company, Dr. Colagiovanni held scientific leadership roles with Nivilas Therapeutics and Replidyne, and she also held research positions with OSI Pharma, Gilead Sciences and Nexstar. Dr. Colagiovanni has a broad range of pharmaceutical development experience, starting with early drug discovery and clinical trials through regulatory approval and commercial launch.

 

For more information, visit http://nextfrontierbio.com/. Follow us on Facebook, Twitter, Instagram and LinkedIn.

Media Contact

Shawna McGregor

917-971-7852

shawna@rosengrouppr.com